This article takes about 4 minutes to read

CURE Basics - 3x Leverage on a Defensive Sector

CURE (Direxion Daily Healthcare Bull 3X Shares) targets 3x the daily return of the Health Care Select Sector Index. Launched June 15, 2011 by Direxion. Expense ratio 0.95%. Net assets ~$500 million. Top holdings: UnitedHealth (~10%), Eli Lilly (~9%), Johnson & Johnson (~7%), AbbVie (~6%), Merck (~5%).

CURE's defining feature is the contradiction of defensive sector times leverage. Healthcare is recession-resistant (people visit doctors regardless of economy), but 3x leverage substantially undermines that stability.

Average daily volume is ~1-2 million shares, lower than TQQQ or SOXL but adequate for retail investors. Liquidity is the most limited among major sector 3x ETFs.

The key question: does healthcare's lower volatility make 3x leverage safer? The answer is nuanced. Decay is lower, but so are returns. And -70% drawdowns are still possible.

Healthcare Sector Characteristics

Healthcare is a classic defensive sector with beta of ~0.7-0.8 versus the market. Drug demand is stable regardless of economic cycles, and aging populations provide structural demand growth.

Annualized volatility is ~14-17%, at or slightly below S&P 500's 15-18%. Much lower than technology (20-25%) or semiconductors (28-35%). This lower volatility directly reduces CURE's decay.

Sector-specific risks include drug pricing regulation, patent cliffs (generic competition), clinical trial failures, and FDA regulatory changes. The 2016 election saw healthcare fall -15%+ on drug pricing fears.

Demographic tailwinds are strong: 65+ populations spend 3-5x more on healthcare than younger cohorts. This structural growth supports CURE's long-term case.

The Defensive Times Leverage Contradiction

The idea that healthcare is stable so 3x leverage is safe is wrong. Decay occurs whenever volatility is non-zero. At 15% volatility, annual decay is -3 × (0.15)² = -6.75%.

This is far below SOXL (-27%) or LABU (-36.75%), but healthcare's annual return is also lower (~+10-12% vs technology's +15-20%). Expected 3x return: 30-36%. After decay: 23-29%.

Compared to SPXL: S&P 500 3×10% - 7.7% = 22.3%. Healthcare 3×11% - 6.75% = 26.25%. CURE outperforms SPXL by ~4% annually, but sector concentration risk makes this margin debatable.

The fundamental contradiction: leveraging eliminates defensiveness. A -15% healthcare decline (occurred in 2016, 2022) becomes -40%+ in CURE. That is not defensive by any definition.

Decay Rate Comparison - Lowest Among Sector 3x ETFs

Comparing decay rates: CURE (healthcare, σ≈15%): -6.75%. SPXL (S&P 500, σ≈16%): -7.7%. FAS (financials, σ≈22%): -14.5%. TECL (technology, σ≈21%): -13.2%. SOXL (semiconductors, σ≈30%): -27%. LABU (biotech, σ≈35%): -36.75%.

CURE has the lowest decay among all sector 3x ETFs. Lower decay means the underlying return is more efficiently amplified to 3x. Over 10 years, CURE's cumulative decay is ~-50% vs SOXL's ~-95%.

CURE can be characterized as a low-risk, medium-return leveraged ETF. Potentially +23-26% annual returns with ~-50% maximum drawdown. Different risk-return profile from TQQQ (+35-40%, -79% max drawdown).

But -50% drawdown is still severe. $10,000 becoming $5,000 is painful. CURE is relatively better than other sector 3x ETFs, not absolutely safe.

Why CURE Is Relatively Better

First, lowest volatility decay. At -6.75% annually, the underlying's +10-12% return comfortably offsets it. Second, smallest maximum drawdown among sector 3x ETFs (~-70% vs TQQQ -79%, SOXL -87%, LABU -95%). Recovery from -70% needs +233% vs +1,900% from -95%.

Third, structurally supported long-term growth from aging populations, medical technology advances, and emerging market healthcare access expansion.

However, relatively better does not mean safe. -70% drawdown means $10,000 becomes $3,000. Most investors find this intolerable regardless of relative comparisons.

CURE is the least risky 3x sector ETF, but it is still a 3x leveraged product with all the inherent dangers that entails.

Portfolio Positioning

Strategy 1: Stability allocation within a leveraged portfolio. TQQQ 15% + CURE 10% + cash 75% combines technology's explosiveness with healthcare's stability.

Strategy 2: Defensive rotation during recession fears. Shift from TQQQ/SOXL to CURE to maintain leverage while reducing downside. Healthcare outperforms during recessions.

Strategy 3: Long-term dollar-cost averaging, leveraging low decay and stable sector growth. Monthly contributions smooth out volatility. But prepare for -70% drawdowns along the way. Healthcare investing books on pharmaceutical business models and regulatory environments improve CURE investment precision.